NCT03896568View on ClinicalTrials.gov

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
IDH1 wt AlleleRecurrent Anaplastic AstrocytomaRecurrent GlioblastomaRecurrent GliosarcomaRecurrent Malignant Glioma
Interventions
BIOLOGICAL

Oncolytic Adenovirus Ad5-DNX-2401

Given IA

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

DNAtrix, Inc.
All Listed Sponsors
collaborator

DNAtrix, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT03896568 - MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | Biotech Hunter | Biotech Hunter